What Is the Best GLP-1 Supplement for Weight Loss? Industry Analysis Reveals Probiotic Akkermansia Formulas as Affordable Ozempic Alternatives




What Is the Best GLP-1 Supplement for Weight Loss? Industry Analysis Reveals Probiotic Akkermansia Formulas as Affordable Ozempic Alternatives

Health Journey Addresses ‘Best GLP-1 Supplement’ Question with Akkermansia-Based Formula Analysis as Six-Month Costs Compare at $294-534 vs. $4,800-7,200 for Pharmaceutical GLP-1

LAKELAND, Dec. 20, 2025 (GLOBE NEWSWIRE) — This educational analysis is sponsored by Health Journey, a dietary supplement company whose GLP-1 Booster product is examined as a case study within this report. While Health Journey has provided support for this research compilation, the scientific citations, industry data, and cost comparisons presented are based on publicly available information. This content is educational only, not medical advice. Readers should consult healthcare providers before starting any supplement, especially those with health conditions, taking medications, or who are pregnant/nursing. Dietary supplements discussed are not FDA-evaluated and are not intended to diagnose, treat, cure, or prevent disease. Individual results vary. Pricing information is subject to change. This article contains affiliate links. If you purchase through these links, a commission may be earned at no additional cost to you. This compensation does not influence the accuracy, neutrality, or integrity of the information presented in this release.

As millions of Americans begin 2026 with renewed commitments to health and weight management, a stark financial reality confronts them: the most effective pharmaceutical weight loss interventions remain financially out of reach for the majority. With prescription GLP-1 medications like Ozempic and Wegovy costing $800-1,200 per month without insurance coverage—and most insurers denying coverage for weight management indications—consumers are increasingly researching affordable alternatives. This has driven explosive growth in the probiotic GLP-1 supplement category, raising the question: what is the best GLP-1 supplement alternative for budget-conscious Americans seeking natural metabolic support in the year ahead?

Complete formulation details are available at the company website.

The timing is particularly relevant as Americans face what public health experts describe as a perfect storm: record obesity rates colliding with economic constraints that make proven pharmaceutical interventions financially inaccessible to average consumers. According to the Centers for Disease Control and Prevention, 42.4% of U.S. adults currently have obesity, while the American Diabetes Association reports that 34.2 million Americans have diabetes. Healthcare costs associated with obesity exceed $173 billion annually, yet the individuals most affected by metabolic health challenges are often those least able to afford the medications that clinical trials have proven most effective.

The Accessibility Crisis Driving Consumer Behavior

The disconnect between pharmaceutical efficacy and financial accessibility has created what industry analysts describe as a two-tier metabolic health system. Clinical trials of pharmaceutical GLP-1 medications have demonstrated substantial weight loss outcomes—typically 15-20% of body weight over 12-18 months. Wegovy (semaglutide 2.4mg) achieved average 15% body weight loss over 68 weeks in pivotal trials, while Zepbound (tirzepatide 15mg) demonstrated average 20.9% body weight loss over 72 weeks. These are robust, well-documented effects that represent genuine breakthroughs in metabolic health treatment.

However, the cost-benefit equation for average Americans creates a significant barrier. At $800-1,200 per month without insurance coverage, a six-month course of pharmaceutical GLP-1 treatment costs $4,800-7,200. Most insurance plans do not cover these medications for weight management indications, only for diabetes treatment with specific clinical criteria. For the majority of Americans—particularly those with modest savings and no insurance coverage for weight management—these costs are prohibitive regardless of clinical efficacy.

This accessibility gap has driven consumer search behavior in predictable directions. Industry data shows that searches for “Ozempic alternative” increased more than 300% in 2024-2025, becoming one of the fastest-growing health-related search terms. Searches for “GLP-1 supplement,” “probiotic GLP-1,” and “natural GLP-1 support” have similarly surged as consumers seek to understand whether more affordable options can provide meaningful metabolic benefits.

The Science Behind Probiotic GLP-1 Support

To understand what probiotic GLP-1 supplements can and cannot deliver, it’s essential to examine the underlying biological mechanisms and research foundation.

GLP-1 (Glucagon-Like Peptide-1) is a hormone produced naturally in the gut by specialized cells called L-cells located in the intestinal lining. When you eat, these L-cells release GLP-1 into the bloodstream, where it performs several metabolic functions: signaling the pancreas to release insulin in response to rising blood glucose, slowing gastric emptying to promote satiety, and interacting with brain appetite centers to influence feelings of fullness.

The gut microbiome connection to GLP-1 production has emerged as an active area of metabolic research over the past decade. Research has demonstrated that certain gut bacteria produce short-chain fatty acids (SCFAs), such as butyrate, when they ferment dietary fiber. These SCFAs can interact with L-cells in the intestinal lining and may influence GLP-1 secretion.

A study published in the Journal of Biological Chemistry in 2015 established the mechanistic link between butyrate-producing bacteria and GLP-1 production at the cellular level. The research demonstrated that butyrate directly stimulates GLP-1 secretion from intestinal L-cells through activation of specific receptors (GPR41 and GPR43, also called free fatty acid receptors FFAR3 and FFAR2). When these receptors are activated by butyrate, they signal L-cells to secrete GLP-1.

Similarly, research on the bacterial strain Akkermansia muciniphila has shown associations between this bacterium’s abundance in the gut and improved metabolic health markers. A randomized controlled trial published in Nature Medicine in 2019 examined pasteurized Akkermansia muciniphila supplementation in 32 overweight and obese insulin-resistant volunteers. After three months, the Akkermansia group showed improvements in insulin sensitivity, reduced insulin levels, and decreased levels of certain inflammatory markers compared with placebo. The study suggested that even pasteurized (heat-treated) Akkermansia retained beneficial metabolic properties.

Additional research published in ASM Journals has explored the crosstalk between glucagon-like peptide 1 and gut microbiota in metabolic diseases, documenting the complex interactions between gut bacteria composition, bacterial metabolites, and GLP-1 signaling pathways.

This body of research forms the scientific foundation that probiotic GLP-1 supplements are built upon: the hypothesis that optimizing gut microbiome composition with specific bacterial strains may support the body’s natural GLP-1 production.

The Critical Distinction: Mechanism and Magnitude

It’s essential to understand that probiotic GLP-1 supplements work through fundamentally different mechanisms than pharmaceutical medications. Prescription GLP-1 drugs like Ozempic, Wegovy, and Mounjaro are synthetic GLP-1 receptor agonists—meaning they bind to and activate the same receptors that natural GLP-1 activates. However, these synthetic versions are engineered to resist breakdown by the DPP-4 enzyme that rapidly degrades natural GLP-1, remain active in the bloodstream for much longer periods (days to weeks versus minutes for natural GLP-1), and achieve blood concentrations far higher than the body naturally produces.

This creates supraphysiological activation of GLP-1 receptors—levels above what the body naturally produces. The magnitude of metabolic effects observed in pharmaceutical trials reflects this supraphysiological mechanism.

Probiotic GLP-1 supplements, by contrast, aim to support the body’s natural production of GLP-1 by optimizing gut microbiome composition. The GLP-1 produced through this pathway is the body’s own natural hormone, which is rapidly broken down by the DPP-4 enzyme as part of normal metabolism. Blood levels remain within physiological ranges—what the body would naturally produce under optimal conditions.

The practical implication: pharmaceutical medications and probiotic supplements operate at different scales, producing effects within different ranges. Pharmaceutical interventions achieve dramatic outcomes documented in clinical trials. Probiotic approaches lack comparable clinical trial data demonstrating weight loss outcomes of similar magnitude. The ingredient-level research on strains like Akkermansia shows associations with improved metabolic markers and modest changes in some studies, but these effects are substantially smaller than pharmaceutical interventions.

Industry analysts emphasize that consumers must align their expectations with the mechanism: probiotic support works within the body’s natural regulatory systems to potentially optimize GLP-1 production within normal ranges, while pharmaceutical medications override natural regulation to achieve supraphysiological effects.

For detailed product specifications, visit the Health Journey website.

What Makes the Best GLP-1 Supplement? Industry Analysis

Based on available research and industry quality standards, experts analyzing the probiotic GLP-1 supplement category suggest consumers evaluate products based on several key criteria when determining what might constitute the best GLP-1 supplement for their individual needs:

Research-Backed Strain Selection

Not all probiotic bacteria influence GLP-1 pathways equally. Research suggests specific strains have documented roles in metabolic health and GLP-1 production mechanisms:

Akkermansia muciniphila has emerged as one of the most extensively researched bacterial strains for metabolic health, earning designation as a “next-generation probiotic” in scientific literature. Research indicates Akkermansia supports gut barrier integrity, influences GLP-1 secretion through mechanisms still being characterized, and modulates immune and metabolic signaling pathways. Studies have used doses ranging from 100 million to 10 billion CFU daily, with beneficial effects observed across this range.

Butyrate-producing strains such as Clostridium butyricum have documented effects on GLP-1 secretion through short-chain fatty acid production. When these bacteria ferment dietary fiber, they produce butyrate, which activates receptors on L-cells that trigger GLP-1 release. Research doses typically range from 20 million to 2 billion CFU.

Supportive strains like Bifidobacterium species help maintain overall microbiome balance, create favorable conditions for other beneficial bacteria, and support gut barrier function and immune modulation. While not directly targeting GLP-1 pathways as extensively as Akkermansia or butyrate-producers, these strains serve important ecosystem support functions.

Industry experts note that targeted combinations of research-selected strains working through complementary mechanisms may offer theoretical advantages over single-strain approaches or generic multi-strain probiotics without metabolic focus.

CFU Count Context and Quality Over Quantity

Consumer confusion often centers on CFU (Colony Forming Unit) counts, with some products advertising 50 billion, 100 billion, or even higher counts. However, research doesn’t support the assumption that higher CFU counts necessarily produce better outcomes.

Studies on Akkermansia, Clostridium butyricum, and Bifidobacterium strains have typically used doses in the millions to low billions range—not the astronomical counts some manufacturers advertise. Industry analysts suggest that CFU inflation beyond research-supported ranges often reflects marketing differentiation rather than evidence-based dosing.

Factors that matter more than raw CFU numbers include: whether strains are research-backed for the intended metabolic purpose, whether bacteria survive manufacturing, storage, and stomach acid to reach the intestines viable, delivery mechanisms such as delayed-release capsules or acid-resistant strains, and storage stability maintaining potency through shelf life.

Products with modest CFU counts (hundreds of millions to low billions) of specifically selected, research-backed strains may offer more value than products with astronomical counts of generic strains lacking metabolic research support.

Synbiotic Design

Probiotic bacteria require fuel to survive and function optimally. Synbiotic formulations combine probiotics with prebiotics—the fiber substrates that beneficial bacteria ferment.

Common prebiotic types include inulin (from chicory root), which is well-researched and preferentially feeds beneficial bacteria including Bifidobacterium species and butyrate-producers; fructooligosaccharides (FOS), which support various beneficial bacteria; resistant starch, which feeds butyrate-producing bacteria; and beta-glucans, which support immune function and beneficial bacteria.

Industry experts note that products combining probiotics with their preferred food sources may offer theoretical advantages over probiotics alone, as they provide both the bacteria and the substrate needed for metabolic byproduct generation. However, prebiotic doses in most probiotic supplements are modest compared to standalone fiber supplements, suggesting dietary fiber intake remains important regardless of supplementation.

Manufacturing Quality and Third-Party Verification

Quality variance is a documented concern in the probiotic supplement category. Independent testing by organizations like ConsumerLab has found that some probiotic supplements contain different strains than labeled or significantly lower CFU counts than advertised.

Key quality markers include: GMP (Good Manufacturing Practices) certification, which represents FDA-mandated quality standards for dietary supplement manufacturing; third-party testing by independent laboratories to verify label claims match actual contents; and transparent disclosure of specific strains (genus, species, and ideally strain designation) rather than proprietary blend language hiding formulation details.

While GMP certification is increasingly standard in the supplement industry, it remains an important baseline quality marker. Third-party testing provides accountability that self-certification alone cannot offer.

Realistic Assessment Windows and Guarantee Alignment

Research on probiotic metabolic interventions typically measures outcomes at 12+ weeks (three months). This timeline allows for stable establishment of probiotic strains, consistent production of bacterial metabolites, time for downstream metabolic effects to potentially emerge, and enough consistency to assess subjective changes in appetite, energy, and wellbeing.

Industry analysts note that guarantee periods should align with realistic assessment timelines. Products offering only 15-30 day guarantees may not provide adequate time for consumers to evaluate whether they experience meaningful benefits. Extended guarantees of 90-180 days better align with research timelines and demonstrate manufacturer confidence in long-term satisfaction.

Transparent and Realistic Positioning

Perhaps the most important criterion for evaluating what constitutes the best GLP-1 supplement is how companies position their products and set consumer expectations.

Red flags that suggest problematic marketing include: claims of pharmaceutical equivalence (“works just like Ozempic”), rapid weight loss promises (dramatic outcomes in short timeframes), proprietary blends without strain disclosure, astronomical CFU counts emphasized over strain quality, and unrealistic guarantee windows preventing adequate assessment.

Conversely, indicators of responsible positioning include: honest acknowledgment that mechanisms differ from pharmaceutical drugs, realistic expectation-setting about gradual metabolic support rather than dramatic transformation, transparent disclosure of all strains and doses, quality manufacturing claims (GMP certification, third-party testing), and guarantee periods aligning with research assessment timelines.

Case Study: Health Journey GLP-1 Booster as Market Example

One example of supplements positioning as accessible GLP-1 support for budget-conscious consumers is Health Journey’s GLP-1 Booster, which industry observers note exemplifies several of the criteria outlined above.

According to Health Journey’s product documentation, the formulation contains three research-backed probiotic strains: Akkermansia muciniphila, studied extensively for metabolic health and GLP-1 pathway associations; Clostridium butyricum, a butyrate-producing strain with documented effects on GLP-1 secretion through short-chain fatty acid production; and Bifidobacterium infantis, which supports overall microbiome balance and gut barrier function.

The product contains 500 Million CFU total, which falls within the lower-to-mid range of research-supported dosing for these specific strains. Studies on Akkermansia have used doses ranging from 100 million to 10 billion CFU, Clostridium butyricum effective doses typically range from 20 million to 2 billion CFU, and Bifidobacterium infantis benefits have been documented with doses from 100 million to 10 billion CFU. The formulation represents research-informed dosing of specifically selected strains rather than arbitrary CFU maximization for marketing purposes.

The product includes 211mg of chicory inulin as prebiotic support. This dose is modest compared to standalone prebiotic supplements, which typically provide 5-20 grams, suggesting the inulin serves a supportive rather than primary role. The synbiotic combination provides both the probiotic bacteria and their preferred food source in a single formulation.

According to the company’s quality documentation, Health Journey GLP-1 Booster is manufactured in GMP-certified facilities and undergoes third-party testing for purity and potency. These quality markers provide baseline assurance that label claims match actual contents, addressing the quality variance concerns documented in the broader probiotic category.

The company offers a 180-day money-back guarantee, which is substantially longer than the industry standard of 30-60 days. This extended guarantee period aligns with the 12+ week research timelines for probiotic metabolic interventions, allowing consumers time to complete a full assessment cycle and still request a refund if the product doesn’t provide perceived value.

According to the company’s published pricing structure, the supplement is available at approximately $49-89 per month depending on package selection. This positions the product at roughly 4-11% of pharmaceutical GLP-1 medication costs. The six-month cost ranges from approximately $294-534, compared to $4,800-7,200 for pharmaceutical interventions over the same period. This price point places the product in the mid-tier of the probiotic GLP-1 category—more accessible than premium products positioned at $150-200 per month while offering research-backed strain selection not typically found in budget options priced at $20-40 per month.

The company’s marketing materials emphasize gut health optimization and metabolic support within the context of comprehensive lifestyle approaches, rather than making pharmaceutical equivalence claims or promising rapid weight loss outcomes. This positioning reflects awareness of the mechanistic differences between probiotic support and pharmaceutical intervention.

The Cost-Benefit Reality Check for Consumers

Understanding the financial tradeoffs helps contextualize what the best GLP-1 supplement might mean for different consumer segments based on budget constraints and health goals.

A six-month comparison illustrates the cost differential:

Pharmaceutical GLP-1 medications (Ozempic, Wegovy, Mounjaro) typically cost $800-1,200 monthly without insurance coverage, resulting in six-month costs of $4,800-7,200. These require prescriptions, ongoing medical supervision, and regular monitoring. Clinical trials document typical outcomes of 15-20% body weight loss over 12-18 months, representing substantial, well-documented metabolic effects.

Mid-tier probiotic GLP-1 supplements typically cost $50-90 monthly, resulting in six-month costs of $300-540. These are available over-the-counter with no prescription requirements or medical supervision needs. Realistic expectations based on ingredient research suggest modest metabolic support rather than pharmaceutical-level weight loss, with effects operating within normal physiological ranges.

Budget-tier probiotic options typically cost $20-40 monthly, resulting in six-month costs of $120-240. These often feature single-strain formulations (Akkermansia only) or generic multi-strain probiotics without metabolic-specific targeting. Quality variance is common in this tier, with less consistent third-party testing and GMP certification.

The cost differential between probiotic supplements and pharmaceutical medications is substantial—probiotic options cost approximately 5-10% of pharmaceutical interventions over six months. However, the magnitude of effect differs proportionally, and consumers must calibrate expectations accordingly.

Financial accessibility makes probiotic GLP-1 support potentially relevant for several consumer segments: individuals without insurance coverage for weight management medications, for whom pharmaceutical options are financially inaccessible regardless of efficacy; consumers with modest metabolic goals seeking 5-10% body weight reduction over 6-12 months rather than the 15-20% documented in pharmaceutical trials; people preferring to exhaust natural approaches before pharmaceutical intervention, viewing supplements as a first step in a progressive strategy; those with injection aversion or needle phobia, for whom the weekly injection requirement of pharmaceutical GLP-1 drugs creates a psychological barrier; and budget-conscious consumers for whom $300-540 over six months is achievable while $4,800-7,200 is not.

Conversely, pharmaceutical GLP-1 medications remain more appropriate for certain situations: medically urgent conditions such as type 2 diabetes with poor control or obesity with serious health complications requiring rapid metabolic improvement; scenarios where the magnitude of effect is critical and 15-20% body weight reduction is medically necessary; situations where adequate medical supervision is available to monitor response and manage potential side effects; and cases where insurance coverage exists or out-of-pocket costs are financially manageable.

For educational resources on probiotic metabolic support, see the company’s informational materials.

Expert Guidance on Realistic Expectations

Nutrition experts and industry analysts emphasize several key points consumers should understand before choosing any product marketed as the best GLP-1 supplement:

The term “GLP-1 supplement” can create misleading expectations if consumers anticipate pharmaceutical-equivalent results. The mechanisms are fundamentally different, producing effects at different scales. Probiotic supplements support natural GLP-1 production within physiological ranges; pharmaceutical drugs achieve supraphysiological activation far beyond natural levels.

Assessment timelines matter significantly. Research on probiotic metabolic interventions typically measures outcomes at 12+ weeks minimum. Consumers should commit to at least 90 days of consistent daily use before evaluating whether subjective benefits—improved satiety patterns, digestive regularity, energy consistency, or general wellbeing—are present. Expecting rapid, dramatic results within days or weeks creates disappointment when probiotic approaches operate on different timescales.

Lifestyle integration is essential for optimal outcomes. Industry analysts note that probiotic metabolic support works best when integrated into comprehensive lifestyle approaches including balanced nutrition with adequate dietary fiber, regular physical activity, sufficient sleep, and stress management. Supplements may enhance good foundations, but they don’t replace them. Expecting a supplement to compensate for poor diet quality, minimal physical activity, inadequate sleep, or unmanaged stress creates unrealistic expectations about what probiotic support can deliver.

Individual variability affects outcomes significantly. Baseline gut microbiome composition, dietary patterns, lifestyle factors, genetic variations, and existing health conditions all influence how individuals respond to probiotic supplementation. What provides meaningful benefits for one person may offer minimal value for another, and there’s no way to predict individual response without trying the product for an adequate assessment period.

Consumers should also watch for red flags indicating problematic products or marketing: companies making pharmaceutical equivalence claims, dramatic before-and-after weight loss promises, proprietary blend language hiding strain disclosure, astronomical CFU counts emphasized without research context, and guarantee windows too short to allow realistic assessment (under 60 days).

The Broader Public Health Context

The question of what constitutes the best GLP-1 supplement for budget-conscious Americans exists within a larger public health challenge: how to address America’s obesity and metabolic health crisis when the most effective treatments remain financially inaccessible to those who need them most.

The healthcare costs associated with obesity—exceeding $173 billion annually according to CDC data—create economic burden extending far beyond individual health outcomes. Yet the individuals most affected by obesity and metabolic dysfunction are disproportionately those with lower incomes and less access to comprehensive health insurance coverage.

Pharmaceutical GLP-1 medications represent genuine scientific breakthroughs, with clinical trial outcomes documenting effectiveness that previous weight loss interventions couldn’t match. However, pricing structures that make these medications accessible primarily to affluent consumers create a troubling two-tier system where metabolic health interventions stratify along economic lines.

The emergence of the probiotic GLP-1 supplement category represents market response to this accessibility gap. While these supplements cannot and do not replicate pharmaceutical outcomes, they provide an option for consumers seeking some form of metabolic support within budget constraints that make pharmaceutical interventions impossible.

Public health experts note that this market dynamic—where expensive but highly effective treatments drive consumer interest in more affordable but less potent alternatives—reflects broader challenges in American healthcare accessibility. The ideal solution would involve making proven pharmaceutical interventions accessible to all who medically need them. In the absence of that accessibility, consumers make pragmatic decisions about what options exist within their financial reality.

Looking Forward: 2026 Market Outlook and Research Directions

Industry observers expect the probiotic GLP-1 supplement category to continue growing throughout 2026 as several factors converge: pharmaceutical GLP-1 pricing remains prohibitive for most Americans without comprehensive insurance coverage; research on gut microbiome-metabolism connections continues advancing, potentially identifying additional beneficial strains or optimal formulation strategies; consumer education improves as understanding of mechanistic differences between probiotic support and pharmaceutical drugs becomes more widespread; and quality manufacturers establish differentiation from opportunistic entrants making exaggerated claims.

Research directions that may inform future probiotic GLP-1 supplement development include: studies examining optimal Akkermansia dosing, delivery mechanisms (live versus pasteurized strains), and colonization strategies; investigation of synergistic strain combinations that may enhance metabolic outcomes beyond single-strain approaches; exploration of individual microbiome profiling to enable personalized probiotic selection based on baseline gut bacteria composition; and long-term outcome studies tracking metabolic changes with sustained probiotic use over 12+ months.

As the category matures, industry analysts anticipate clearer differentiation between responsible manufacturers making evidence-based claims and opportunistic entrants making pharmaceutical equivalence promises that research doesn’t support. Consumer protection may benefit from this differentiation, as informed consumers learn to evaluate products based on research-backed criteria rather than marketing hype.

The fundamental question—what is the best GLP-1 supplement for budget-conscious Americans?—ultimately depends on individual circumstances, health goals, budget constraints, and willingness to commit to gradual metabolic support rather than rapid pharmaceutical intervention. What’s increasingly clear is that the accessibility gap created by pharmaceutical pricing has driven genuine category innovation, and consumers entering 2026 with health improvement goals have supplement options that didn’t exist even two years ago.

For consumers evaluating these options, the research suggests focusing on products with documented strain selection, transparent dosing aligned with research, quality manufacturing standards, realistic positioning about mechanisms and outcomes, and guarantee periods allowing adequate assessment time. The goal is matching individual needs and expectations with products that can realistically deliver value within budget constraints—recognizing that “best” means different things depending on whether the priority is maximum effect (pharmaceutical), optimal cost-benefit balance (mid-tier probiotic), or minimum financial commitment (budget probiotic).

As millions of Americans begin 2026 with renewed health commitments, understanding these options and tradeoffs empowers more informed decision-making about which approach—if any—aligns with individual health situations, financial realities, and realistic outcome expectations.

About Health Journey

Health Journey is a dietary supplement company focused on gut health and metabolic wellness. The company’s GLP-1 Booster combines research-backed probiotic strains (Akkermansia muciniphila, Clostridium butyricum, and Bifidobacterium infantis) with prebiotic support to provide accessible metabolic support for consumers seeking natural approaches to wellness. The product is manufactured in GMP-certified facilities and undergoes third-party testing for purity and potency. Additional information is available on the company website.

Contact Information:

Health Journey Email: care@shophealthjourney.com Phone: 855-293-8566 Website: https://tryglp1booster.com

Contact:

For inquiries contact Health Journey customer service at the email and phone number listed above.

Disclaimer: This article is for informational and educational purposes only and does not constitute medical advice. Consumers should consult qualified healthcare providers before starting any new dietary supplement, particularly if they have existing health conditions, take medications, are pregnant or nursing, or are considering significant changes to their health regimen. Individual results with any supplement vary based on baseline health status, dietary patterns, lifestyle factors, and genetic variables. The research discussed examines individual probiotic strains and metabolic pathways; Health Journey GLP-1 Booster as a finished product has not been independently studied in clinical trials. Probiotic supplements are not intended to diagnose, treat, cure, or prevent any disease. Results are not guaranteed, and dietary supplements should not replace prescribed medical treatment for diagnosed conditions.

Scientific References:

Beneficial Metabolic Effects of a Probiotic via Butyrate-induced GLP-1 Hormone Secretion, Journal of Biological Chemistry: https://www.jbc.org/article/S0021-9258%2820%2949115-X/fulltext

Crosstalk between glucagon-like peptide 1 and gut microbiota in metabolic diseases, ASM Journals: https://journals.asm.org/doi/10.1128/mbio.02032-23

Akkermansia muciniphila and improved metabolic health, Nature Medicine: https://www.nature.com/articles/s41591-019-0495-2

Obesity statistics and healthcare costs, Centers for Disease Control and Prevention: https://www.cdc.gov/obesity/data/adult.html

Diabetes statistics, American Diabetes Association: https://diabetes.org/about-diabetes/statistics/about-diabetes

END OF RELEASE

###

CONTACT: Health Journey Email: care@shophealthjourney.com 
Phone: 855-293-8566